Entrada Therapeutics, Inc. (TRDA)
6.57
-0.54
(-7.59%)
USD |
NASDAQ |
Sep 10, 13:28
Entrada Therapeutics Shareholders Equity (Quarterly) : 233.41M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 233.41M |
| March 31, 2026 | 270.85M |
| December 31, 2025 | 306.13M |
| September 30, 2025 | 340.72M |
| June 30, 2025 | 379.50M |
| March 31, 2025 | 417.26M |
| December 31, 2024 | 428.68M |
| September 30, 2024 | 422.45M |
| June 30, 2024 | 429.92M |
| March 31, 2024 | 269.37M |
| December 31, 2023 | 242.36M |
| September 30, 2023 | 246.66M |
| Date | Value |
|---|---|
| June 30, 2023 | 206.91M |
| March 31, 2023 | 229.61M |
| December 31, 2022 | 212.55M |
| September 30, 2022 | 233.22M |
| June 30, 2022 | 256.04M |
| March 31, 2022 | 277.39M |
| December 31, 2021 | 298.72M |
| September 30, 2021 | 124.90M |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 40.17M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 298.88M |
| Total Liabilities (Quarterly) | 65.47M |
| Debt to Equity Ratio | 0.208 |
| Current Ratio | 10.89 |
| Net Debt Paydown Yield | 0.59% |